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Abstract: The renin-angiotensin-aldosterone system (RAAS) is an important mediator of blood 
pressure (BP) and volume regulation in both normotensive and hypertensive persons and is a 
major contributor to hypertension-related target organ damage. The concept of renin inhibition for 
managing hypertension by blocking the RAAS pathway at its point of activation is very attractive 
since the renin-angiotensinogen reaction is the first and rate-limiting step in the generation of 
angiotensin II (Ang II). Aliskiren, the first in a new class of orally effective direct renin inhibitors 
(DRIs), is approved for the treatment of hypertension. It is effective in reducing BP in the general 
population of hypertensive patients and in special patient groups such as obese persons, and has 
a tolerability and safety profile similar to placebo. Aliskiren has renoprotective, cardioprotective 
and anti-atherosclerotic effects in animal models that appear to be independent of BP lowering. 
It reduces proteinuria in diabetic patients and has favorable neurohumoral effects in patients with 
symptomatic heart failure. Additional outcome trials are needed to establish the role of this novel 
class of antihypertensive medication in the therapeutic armamentarium.
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Biology of the renin-angiotensin-aldosterone system
The renin-angiotensin-aldosterone system (RAAS) is an important mediator of 
blood pressure (BP) and extracellular fluid volume regulation in both normotensive 
and hypertensive persons. Renin is an aspartyl protease that is synthesized as a 
preprohormone, cleaved and stored in an inactive (prorenin) form in the juxtaglomerular 
cells surrounding the afferent arterioles in the kidney.1 Prorenin is rendered enzymatically 
active by both proteolytic and nonproteolytic processes (Figure 1). Most proteolytic 
activation of prorenin occurs within the juxtaglomerular cells by cleavage of its 43 amino 
acid N-terminal pro-segment.1 Nonproteolytic activation is a 2-step process that allows 
prorenin that has been secreted from the juxtaglomerular cells into the circulation to 
acquire enzymatic activity without removal of the pro-segment. While both prorenin and 
active renin are secreted from the juxtaglomerular cells into the circulation in response 
to reductions in glomerular afferent arteriolar pressure, sympathetic nerve stimulation 
or reduced sodium delivery to the macula densa, prorenin is the predominant circulating 
form, accounting for approximately 90% of total renin in normal human plasma and 
for an even greater portion of the total in diabetic patients.2,3
Active renin catalyzes the formation of angiotensin I (Ang I) from angiotensinogen. 
Ang I, in turn, is processed by angiotensin-converting enzyme (ACE) and other 
proteases to form angiotensin II (Ang II), an important secretagogue for aldosterone 
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For the first century of its existence, renin was thought to 
have no function other than catalysis of the generation of Ang 
I from angiotensinogen. However, the discovery of a direct 
receptor for renin and prorenin, referred to as the (pro)renin 
receptor, has redefined the biology of the RAAS (Figure 2).4 
Activation of this receptor by renin or prorenin both facilitates 
angiotensin generation and triggers a signal transduction path-
way that is distinct from Ang II receptor signaling.5,6 Impor-
tantly, binding of prorenin to the (pro)renin receptor changes 
its configuration and exposes its active site, rendering it fully 
catalytically active (Figure 1).7
Nonproteolytic activation of prorenin can be triggered 
by binding of its pentameric “handle region” (I11PLLKK15P) 
to the (pro)renin receptor, resulting in RAAS activation and 
target organ damage.8,9 In the stroke-prone spontaneously 
hypertensive rat (SHRsp) fed a high salt diet, inhibition of 
nonproteolytic prorenin activation using a decoy peptide 
that spans the pentameric handle region has been shown 
to inactivate the tissue RAAS in heart and to attenuate the 
development and progression of cardiac fibrosis without 
affecting the circulating RAAS or arterial pressure. In the 
kidney of salt fed SHRsp, the majority of nonproteolytically 
activated prorenin has been localized to the glomerular podo-
cytes, the site at which RAAS activation, proteinuria and 
glomerulosclerosis occur. In this setting, the decoy peptide 
completely inhibits nonproteolytic activation of prorenin and 
activation of the intrarenal RAAS and significantly attenuates 
the progression of proteinuria and nephrosclerosis without 
affecting the circulating RAAS or lowering arterial pressure. 
Taken together, these findings provide strong evidence that 
(pro)renin receptor mediated nonproteolytic activation of 
tissue prorenin is an important mediator of both cardiac and 
renal damage in hypertension.
(Pro)renin receptors have been described in a variety 
of cell types, including glomerular mesangial cells, 
human brain, heart, liver, pancreas, kidneys, lung, skeletal 
muscle placenta, retina, vascular smooth muscle cells and 
cardiomyocytes.4,6,10 Studies using transgenic rats that 
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Figure 1 Proteolytic and non-proteolytic activation of prorenin. A renin inhibitor will increase the amount of nonproteolytically activated prorenin. Such a drug binds to 
prorenin when it is in its open active conformation. Once bound, the prosegment cannot regain its original “closed” position, and thus prorenin will now be recognized by 
antibodies directed against the active site, although of course it is incapable of generating angiotensin (Ang) I from angiotensinogen (Aog). Because of the high affinity of the 
renin inhibitor, prorenin will stay in the “open” conformation, and thus the equilibrium will shift into the direction of the open conformation. eventually, all prorenin will be 
in the open conformation. Reproduced with permission From Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005;46:1069–1076.7 
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express the human (pro)renin receptor genes demonstrate that 
activation of the (pro)renin receptor can stimulate various 
intracellular signaling pathways, thus triggering the expres-
sion of genes that contribute to BP elevation and related target 
organ damage. For example, transgenic rats that overexpress 
the human (pro)renin receptor gene in smooth muscle cells 
under the control of the mouse smooth muscle myosin heavy 
chain gene develop a cardiovascular phenotype with elevated 
systolic BP and heart rate.11 These findings are associated 
with increases in plasma aldosterone and aldosterone/renin 
ratio in the presence of normal plasma renin, possibly related 
to the intraadrenal activation of the RAAS.
Binding of human recombinant renin to the (pro)renin 
receptor in mesangial cells has been shown to provoke phos-
phorylation of the mitogen-activated protein (MAP) kinases 
ERK1(p44) and ERK2(p42), which in turn upregulates the 
expression of profibrotic molecules such as transforming 
growth factor (TGF)-β, plasminogen activator inhibitor 
(PAI)-1, collagen I and fibronectin.4,12 These effects of 
(pro)renin receptor activation, which are independent of 
Ang II, may lead to increased tissue fibrosis and cellular 
hypertrophy, resulting ultimately in cardiovascular and 
renal outcomes.13 Further, prorenin has been shown to exert 
angiotensin-independent effects, including stimulation of the 
p38 MAP kinase/HSP 27 pathway, with resultant alterations 
in actin filament dynamics, in isolated neonatal cardiomyo-
cytes that express the (pro)renin receptor.10 These effects 
suggest that prorenin, via the (pro)renin receptor, can directly 
affect cardiac growth and development.
The observation that plasma prorenin levels are 
associated with the microvascular complications of diabetes, 
including retinopathy and nephropathy, has suggested 
that prorenin may contribute to target organ damage in 
humans.14–16 Evidence from streptozotocin diabetic mice 
has given proof of principle that binding of prorenin to 
the (pro)renin receptor in kidney can induce diabetic 
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Figure 2 Schematic representation of the renin-angiotensin-aldosterone system. ACe, angiotensin-converting enzyme; Ang, angiotensin (roman numerals refer to the 
nomenclature for the peptide; numbers in parentheses refer to the amino acid positions in the peptide relative to Ang i, which has 10 amino acids); AT1, angiotensin ii type 1 
receptor;   AT2, angiotensin ii type 2 receptor. Adapted from Reudelhuber TL. Renin. in: Oparil S, weber MA (eds). Hypertension, 2nd ed. A Companion to Brenner and Rector’s The 
kidney. Philadelphia: elsevier, 2005, p. 89–94.63 Copyright © 2005 elsevier.Vascular Health and Risk Management 2009:5 456
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nephropathy by an Ang II independent mechanism that does 
not require proteolytic activation of prorenin.17 Building 
on the observation that the prorenin-to-active renin ratio is 
increased in diabetes, the investigators tested the hypoth-
esis that prorenin can promote the development of diabetic 
nephropathy by (pro)renin receptor mediated mechanisms 
that do not require activation of the RAAS. Wild type and 
Ang II type 1a receptor gene-deficient (ATKO) mice were 
treated with streptozotocin to induce diabetes and then with 
either an ACE inhibitor or the decoy peptide discussed above 
and the effects of the treatments on progression of diabetic 
nephropathy were observed. The decoy peptide completely 
prevented the development of diabetic nephropathy and acti-
vation of renal MAP kinases in both wild type and ATKO 
diabetic mice, demonstrating the AngII independence of 
its action. In contrast, the ACE inhibitor, administered at 
doses sufficient to suppress circulating and intrarenal AngII 
levels, had only a partial effect on the progression of renal 
disease. Whether these provocative preclinical findings can 
be translated to the setting of human diabetes is a question 
for future investigation.
Inhibitors of the renin-angiotensin-
aldosterone system
Increased RAAS activity, particularly increased Ang II 
and aldosterone levels, contribute to target organ damage 
and enhance cardiovascular risk both by elevating BP and 
through direct effects on vascular endothelium and cardiac 
and renal tissues.3 Ang II promotes target organ damage 
through BP elevation and by mediating constriction and 
remodeling of resistance vessels, aldosterone synthesis and 
release, enhancement of sympathetic outflow from the brain, 
and facilitation of cathecolamine release from the adrenals 
and peripheral sympathetic nerve terminals.18,19 Ang II is 
also vasculotoxic due to stimulation of oxidative reactions, 
such as increasing NAD(P)H oxidase, and promotes cardiac 
and vascular smooth muscle cell hypertrophy by stimulating 
expression of a number of growth factors and cytokines and 
their receptors.
Agents that antagonize the RAAS at various steps, 
including beta blockers, ACE inhibitors, Ang II receptor 
blockers (ARBs) and aldosterone antagonists, have been 
used effectively to lower BP, limit or reverse various forms 
of target organ damage and improve outcomes in patients 
with hypertension and/or chronic kidney disease, coronary 
artery disease, left ventricular hypertrophy and heart failure. 
Direct renin inhibitors (DRIs), developed as the newest class 
of antihypertensive agents, block the RAAS at its point of 
origin, the renin-angiotensinogen reaction, and offer a novel 
approach to the prevention or reversal of target organ damage 
and cardiovascular events.
Aliskiren
Aliskiren is the only orally active DRI approved for the 
treatment of hypertension in humans.20 It is a competitive 
transition state analog and selective inhibitor of human 
renin. It has a therapeutic potential similar to that of other 
antagonists of the RAAS.21 In humans, the plasma concen-
tration of aliskiren increases dose-dependently after oral 
administration in doses of 40 to 640 mg/day, peaking after 
3 to 6 hours.22 The average plasma half-life is 23.7 hours, 
ranging from 20 to 45 hours, making aliskiren suitable 
for once-daily administration. The oral bioavailability of 
aliskiren in humans is limited (2.7%).22 Aliskiren is 47% 
to 51% protein bound and the steady-state plasma concen-
tration is reached after 5 to 8 days of treatment. The main 
elimination route of aliskiren is via biliary excretion as 
unmetabolised drug.22
Aliskiren is more potent and selective for human renin 
than the other orally active DRIs, ie, remikiren and enalkiren. 
It is not metabolized by cytochrome P450, and thus has 
low potential for significant interactions with other drugs, 
eg, warfarin, lovastatin, digoxin, valsartan, amlodipine, 
metformin, celecoxib, atenolol, atorvastatin, ramipril and 
hydrochlorothiazide (HCTZ).23–26
Aliskiren effectively blocks the generation of active renin 
and of downstream components of the RAAS in both nor-
motensive and hypertensive human subjects. In this respect 
the DRI differs from the ACE inhibitors and ARBs, which 
attenuate feedback inhibition of renin synthesis and release 
by Ang II, resulting in a reactive rise in plasma renin activity 
(PRA). A double-blind cross-over study in healthy volunteers 
receiving a low-sodium diet evaluated the effects of 4 oral 
doses of aliskiren (40, 80, 160, and 640 mg/day) compared 
with placebo and the ACE inhibitor enalapril (20 mg) on 
components of the RAAS.22 Aliskiren reduced PRA in a 
dose-dependent manner after both a single oral dose and 
8 days of repeated once-daily dosing. The highest doses of 
aliskiren reduced Ang II levels by a maximum of 89% and 
75% on days 1 and 8, respectively, compared with placebo, 
and aliskiren 80 mg/day decreased plasma and urinary 
aldosterone levels by 40% and 50%, respectively. Enalapril 
reduced Ang II levels similarly to aliskiren, but increased 
PRA 15-fold. Later studies confirmed that aliskiren increases 
plasma renin content, but reduces PRA, presumably by bind-
ing to the active site of renin.27 Importantly, this study also Vascular Health and Risk Management 2009:5 457
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showed that circulating concentrations of prorenin did not 
increase in response to aliskiren.
The hormonal effects of dual RAAS blockade with 
aliskiren and the ARB valsartan have been evaluated and 
compared with the effects of each monotherapy and placebo 
in both sodium-depleted normotensive individuals and in 
hypertensive patients28,29 Valsartan monotherapy increased 
PRA, Ang I and Ang II, while PRA, Ang I and Ang II levels 
with aliskiren monotherapy and with combination therapy 
were similar to placebo, indicating that the addition of 
aliskiren to valsartan eliminates the compensatory increase 
in PRA and Ang II caused by ARBs.
Although aliskiren suppresses PRA, it causes major 
reactive increases in plasma renin concentration. This has 
led some to hypothesize that reactive renin secretion may 
limit the effectiveness of DRIs.30,31 They reason that, if the 
RAAS is at all leaky, allowing even a small percentage 
of the excess prorenin generated during DRI treatment 
to be activated, the antihypertensive effect of the DRI 
may be offset, limiting its utility as an antihypertensive 
agent. However, this theory is controversial and has been 
questioned.32 Further, Feldman et al recently demonstrated 
that aliskiren inhibits prorenin by reducing the (pro)renin 
receptor expression and binding to the active site of 
prorenin.33 It has also been suggested that the DRIs 
have limited ability to reduce BP in patients with low 
baseline PRA levels, thus limiting their utility, at least as 
monotherapy, in the general population of hypertensive 
patients.31 Additional study and clinical experience with 
aliskiren and other DRIs, as they become available, are 
needed to validate or refute this hypothesis.
Aliskiren in the treatment 
of hypertension
Aliskiren, both as monotherapy and in combination with 
other agents, has been evaluated extensively in hypertensive 
patients.29,34,35 Aliskiren monotherapy (75–300 mg/day) has a 
dose-dependent antihypertensive effect that is comparable to 
that seen with other major classes of antihypertensive drugs and 
is associated with a placebo level of side effects.36 Comparator 
studies have shown that aliskiren is as effective as HCTZ, the 
ARBs irbesartan, losartan and valsartan, the calcium channel 
blocker amlodipine and the beta blocker atenolol and may 
be slightly more effective than ACE inhibitors in lowering 
BP.3,37 Further reductions in BP are seen when aliskiren is 
combined with antihypertensive drugs from the other major 
classes, including RAAS blockers.29 Moreover, combination of 
aliskiren with other antihypertensive agents is a useful strategy 
in patients who do not respond to aliskiren monotherapy.38 For 
example, in one large study that included almost 900 patients, 
a single-pill combination of aliskiren with HCTZ provided 
significantly greater BP reduction than aliskiren alone with 
similar tolerability. Most recently, aliskiren-based therapy 
(monotherapy ± amlodipine if needed) has been shown to be 
more effective than HCTZ-based therapy in reducing BP in 
a study of 1124 hypertensive patients who were followed for 
1 year.39
Aliskiren in special populations
Obesity
There is a strong positive relationship between body mass 
index (BMI) and the prevalence of hypertension.40,41 Risk 
estimates from the Framingham Heart Study suggest that 
65% to 75% of cases of hypertension are attributable 
to overweight and obesity.42 Further, hypertension in 
overweight and obese persons is difficult to control, with 
reported control rates of less than 20%.43 Pathophysiologic 
factors in obesity-related hypertension include both 
volume expansion and activation of the RAAS, suggesting 
that RAAS blockade might be a beneficial management 
strategy.44 A randomized double-blind study carried out 
in 489 obese (average BMI 34.4 kg/m2) hypertensive 
patients that had not achieved BP goals with HCTZ 
monotherapy compared the antihypertensive efficacy 
of aliskiren, irbesartan, amlodipine and placebo based 
treatment added to HCTZ (25 mg).45 After 8 weeks of 
double-blind treatment, aliskiren/HCTZ lowered BP by 
15.8/11.9 mm Hg, significantly more than placebo/HCTZ 
(8.6/7.9 mm Hg). Aliskiren/HCTZ provided BP reductions 
similar to those with irbesartan/HCTZ and amlodipine/
HCTZ, with similar tolerability to placebo/HCTZ. Adverse 
event rates were highest with amlodipine/HCTZ because 
of a higher incidence of peripheral edema. This study 
demonstrates that combination treatment with aliskiren is 
an effective and well-tolerated therapeutic option for obese 
patients with hypertension who fail to achieve BP control 
with thiazide diuretic treatment, a growing and difficult to 
manage subgroup of the hypertensive population.
Diabetes
The RAAS has been implicated in both the pathogenesis and 
the vascular complications of diabetes. Evidence from the trans-
genic rat that harbors the mouse renin gene (TG(mRen-2)27), a 
model of tissue renin overexpression which results in hyperten-
sion, insulin resistance, and cardiovascular and renal damage, 
suggests that local expression of the RAAS in the pancreas Vascular Health and Risk Management 2009:5 458
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damages the organ by stimulating NADPH oxidase, thus 
generating reactive oxygen species.46 Treatment of Ren2 rats 
with aliskiren has been shown to normalize systemic insulin 
resistance and islet insulin, Ang II and NADPH activity. If 
translatable to the human condition, these findings suggest that 
DRI treatment could prevent diabetes and the components of the 
metabolic syndrome. As discussed below, preclinical studies 
have also demonstrated antihypertensive and renoprotective 
effects of aliskiren in animal models of diabetes.
Hypertension is highly prevalent and relatively resistant 
to treatment in diabetic patients, necessitating multiple drug 
treatment in the majority of cases. The antihypertensive 
efficacy and safety of aliskiren alone and in combination 
with the ACE inhibitor ramipril have been tested in a 
double-blind trial carried out in 837 hypertensive diabetic 
patients.47 While all therapies produced significant reductions 
in 24 hour ambulatory BP, aliskiren monotherapy was 
superior to ramipril monotherapy in reducing systolic BP 
and noninferior in reducing diastolic BP. Importantly, the 
combination provided an additional mean BP reduction of 
4.6/2.1 mmHg over ramipril monotherapy and was well 
tolerated. These findings suggest that a DRI-ACE inhibitor 
combination provides an effective and safe therapeutic option 
for the hypertensive diabetic patient.
Renoprotective effects of aliskiren
Preclinical studies have shown that aliskiren, like other 
RAAS inhibitors, has renoprotective effects in both diabetic 
and nondiabetic models of chronic kidney disease. Aliskiren 
has been shown to induce a dose dependent decrease in BP 
and to prevent progressive albuminuria in streptozotocin 
treated TG(mRen-2)27 rats.33 Aliskiren also suppressed 
renal expression of TGF-β, collagen I and the (pro)renin 
receptor in this model. The renoprotective effect of aliskiren 
in this study was attributed to its extensive partitioning to the 
kidney, achieving a kidney/plasma concentration ratio of over 
60 at 2 weeks of treatment. Extensive binding of aliskiren 
to glomeruli and small cortical blood vessels was found by 
autoradiography. Finally, aliskiren was found to bind to the 
active site of prorenin, suggesting that (pro)renin receptor-
mediated activation of prorenin and the consequent gain in 
Ang II forming ability may be neutralized by aliskiren. These 
findings provide evidence that tissue damage related to Ang 
II generated by (pro)renin receptor-bound, nonproteolytically 
activated prorenin or prorenin that is proteolytically activated 
in tissues should be reduced by aliskiren. The authors 
speculated that aliskiren may inhibit fibrosis in the kidney 
by suppressing (pro)renin receptor gene expression, thus 
reducing receptor number and attenuating prorenin-induced 
profibrotic signaling, by preventing activation of prorenin and 
by negating the gain in catalytic activity of receptor-bound 
renin. The role of these mechanisms in the pathogenesis 
of diabetic nephropathy in either animal models or human 
subjects remains to be demonstrated.
Renoprotective effects of aliskiren have also been 
demonstrated in double transgenic rats (dTGR) that express 
genes for both human renin and angiotensinogen. Aliskiren 
has been compared to valsartan in preventing target-organ 
damage in dTGR.48 Both low- and high-dose aliskiren and 
high-dose valsartan lowered BP, reduced albuminuria and 
creatinine levels, attenuated left ventricular (LV) hypertrophy 
and increased survival in this model. Anti-inflammatory 
effects of aliskiren and the ARB losartan have also been 
demonstrated in the kidney of dTGR.49 In another rat model of 
advanced diabetic nephropathy, aliskiren reduced albuminu-
ria and other markers of renal damage, including expression 
of TGF-β and collagens III and IV.50 When aliskiren was 
compared with ACE inhibitors or ARBs in these models, 
the renal and cardiac protective effects were approximately 
equal.48,50
Following the proof of principle elucidated by the 
animal models, the hypothesis that aliskiren can provide 
renoprotection by reducing albuminuria in patients with dia-
betes has been tested.51,52 Both 24-hour systolic BP assessed 
by ambulatory monitoring and urinary albumin/creatinine 
ratio decreased significantly with aliskiren treatment in a 
study of 15 patients with type 2 diabetes, hypertension and 
proteinuria (Figure 3).51 The more robust Aliskiren in the 
Evaluation of Proteinuria in Diabetes (AVOID) study tested 
whether dual RAAS blockade achieved by adding aliskiren 
to the maximal recommended dose of an ARB (losartan) and 
optimal antihypertensive therapy would reduce albuminuria 
in 599 patients with hypertension, type 2 diabetes and 
proteinuria at baseline.52 Addition of aliskiren to ARB 
treatment reduced the mean urinary albumin-to-creatinine 
ratio by 20%, (Figure 4), with a reduction of 50% or more in 
24.7% of the patients. A non-significant 2/1 mmHg difference 
in BP was seen between the treatment groups, suggesting 
that the renoprotective effect of aliskiren was independent of 
BP. The total numbers of adverse and serious adverse events 
were similar in the groups.
It has been suggested that DRIs may provide more 
complete and thus more effective blockade of the RAAS 
than standard recommended treatment with ACE inhibitors 
or ARBs and, therefore, may be more renoprotective. To test 
this hypothesis, the response of renal plasma flow (RPF), Vascular Health and Risk Management 2009:5 459
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a measure of intrarenal renin activity, to treatment with 
aliskiren or an ACE inhibitor (captopril) was measured in 
20 healthy normotensive subjects whose RAAS was activated 
by consumption of a low-sodium diet.27 The RPF response 
to aliskiren was maximal at the 600 mg dose (twice the 
maximal recommended dose for hypertension treatment) 
and exceeded responses to captopril observed in this study, 
as well as responses seen previously to both ACE inhibitors 
and ARBs. Residual vasodilation was observed 48 hours 
after each dose, and aliskiren treatment was associated with 
significant natriuresis. The authors concluded that DRI treat-
ment promises to provide more complete blockade of the 
RAAS than treatment with other RAAS blockers and there-
fore has potential for greater organ protection and improved 
clinical outcomes, particularly in hypertensive patients with 
concomitant cardiovascular disease.
Anti-atherosclerotic effects 
of aliskiren
Animal experiments and human studies have demonstrated 
that pharmacological blockade of the RAAS has beneficial 
effects on atherosclerosis that seem to be independent 
of BP lowering.53,54 The beneficial effects of aliskiren on 
atherosclerosis progression have been compared to those 
of a representative ARB (irbesartan), a representative beta 
blocker (atenolol), and a representative calcium channel 
blocker (amlodipine) in a mouse model of atherosclerosis.55 
Two-kidney, 1-clip renovascular hypertension was induced 
in ApoE-/- mice to generate a model with vulnerable 
atherosclerotic plaques and 1-kidney, 1-clip renovascular 
hypertension was induced to generate a model with stable 
plaques. Aliskiren and irbesartan significantly attenu-
ated atherosclerosis progression in 2-kidney, 1-clip mice 
compared to untreated animals. Plaques in these animals also 
showed thinner fibrous caps, smaller lipid cores, decreased 
media degeneration, layering, and macrophage content, and 
increased smooth muscle cell content. Aliskiren increased the 
smooth muscle cell content to a significantly greater extent 
than irbesartan. If these results are confirmed in clinical 
studies, patients with clinical or subclinical atherosclerosis 
could benefit with RAAS blockade with a DRI.
There is also evidence that the DRI aliskiren protects 
against spontaneously occurring atherosclerosis in the 
Watanabe heritable hyperlipidemic rabbit by improving 
endothelial function.56 Watanabe rabbits were treated 
with aliskiren, valsartan, aliskiren plus valsartan or vehi-
cle for 8 weeks and nitric oxide (NO) bioavailability and 
atherosclerotic plaque area in the aorta were assessed. 
Acetylcholine-induced NO production, a surrogate 
index of endothelial protection, was significantly greater 
with aliskiren+valsartan than with either monotherapy, 
indicating improvement in endothelial function with 
1 2–4 5–7 8–10 11–13 14–16 17–19 20–22 23–25
26–28
29–31 32–34 35–37 38–40 41–43 44–46 47–49 50–52 53–54
110
120
130
140
150
160
170
180
190
200
Treatment
Day
Washout
U
A
C
R
 
(
m
g
 
g
–
1
)
Figure 3 Urinary albumin/creatinine ratio in diabetic patients with micro- or macroalbuminuria treated with aliskiren for 28 days followed by 28 days washout. Reproduced 
with permission from Persson F, Rossing P, Schjoedt KJ, et al.   Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. 
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the combination. Similarly, plaque area was decreased to 
a significantly greater extent with combination therapy 
compared with either monotherapy.
A recent study in the fat-fed LDL receptor-deficient 
mouse (Ldlr-/-) has revealed a novel mechanism by which 
DRI treatment attenuates the development of atheroscle-
rosis.57 Aliskiren treatment produced dose dependent 
reductions in atherosclerotic lesion size in this model, 
supporting the RAAS dependence of the atherosclerotic 
process. To test whether local expression of RAAS compo-
nents, including renin and the AT1a receptor, in the arterial 
wall played a role in the progression of atherosclerosis, the 
authors took advantage of previous observations that macro-
phages in culture express renin, angiotensinogen and AT1a 
receptors. To determine whether macrophage expression 
of renin contributed to the progression of atherosclerosis, 
they generated chimeric mice with renin deficient bone 
marrow-derived cells (mostly macrophages) by irradiating 
Ldlr-/- mice and repopulating with bone marrow-derived 
cells from renin-/- mice. There was a profound decrease in 
atherosclerotic lesion size in the chimeric mice, supporting a 
role for local macrophage-derived renin in the pathogenesis 
of atherosclerosis in this model. In similar experiments, 
transplantation of bone marrow from AT1a receptor-/- mice 
failed to influence lesion development, demonstrating that 
macrophages are not target cells for Ang II in the pathogen-
esis of atherosclerosis in this model. Subsequent experiments 
showed that peritoneal macrophages from renin-/- mice had 
a significantly reduced ability to induce monocyte adhesion 
to endothelial cell monolayers, suggesting that endothelial 
AT1a receptors are targets for macrophage-derived AngII 
in the setting of murine atherosclerosis. Further study is 
needed to determine whether these mechanisms are shared 
by humans.
Cardioprotective effects of aliskiren
Direct renin inhibition with aliskiren attenuates cardiac 
dysfunction in animal models. The effect of DRI treatment 
on cardiac remodeling, apoptosis and LV function after 
experimental myocardial infarction has been examined 
in wild type mice that were subjected to coronary artery 
ligation, then treated with aliskiren or vehicle for 10 days.58 
Aliskiren treatment improved diastolic and systolic 
LV function and decreased post-myocardial infarction 
hypertrophy, apoptosis, and matrix metalloproteinase 
activity without altering BP.
There is evidence that aliskiren reduces LV hypertrophy 
as effectively as an ARB. In the Aliskiren Left Ventricular 
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Assessment of Hypertrophy (ALLAY) study, 460 overweight 
hypertensive patients were randomized to receive aliskiren, 
losartan, or a combination of the two.59 Other antihyperten-
sives could be added as necessary. Aliskiren was noninferior 
to losartan in reducing LV mass index, but the combination 
was not superior to losartan alone. These findings suggest 
that aliskiren is an effective and well-tolerated treatment 
option for patients with LV hypertrophy.
Since loss of negative feedback inhibition of renin 
release during chronic treatment with ACE inhibitors leads 
to a compensatory rise in renin secretion and downstream 
components of the RAAS cascade, thereby possibly attenu-
ating the benefit of the treatment, it has been hypothesized 
that addition of a DRI to chronic ACE inhibitor treatment 
would benefit patients with heart failure. The Aliskiren 
Observation of Heart Failure Treatment (ALOFT) study 
tested this hypothesis in 302 patients with New York Heart 
Association class II to IV heart failure and plasma brain-type 
natriuretic peptide (BNP) concentrations 100 pg/mL who 
were being treated with a beta blocker and an ACE inhibitor 
or ARB.60 Compared with placebo treated controls, patients 
randomized to aliskiren showed significant improvement in 
neurohormonal profiles, including reductions in PRA, BNP 
and N-terminal prohormone BNP (NT-proBNP) levels in 
plasma and urinary aldosterone concentrations without 
adverse effects. The findings of ALOFT support further trials 
to test the safety and efficacy of aliskiren in patients with 
heart failure, either as an alternative to or in combination 
with other blockers of the RAAS.
Ongoing studies
Ongoing studies are testing whether the DRI aliskiren is 
effective in prevention or regression of various forms of target 
organ damage in humans. The Safety and Efficacy of Aliskiren 
in Post Myocardial Infarction Patients (ASPIRE) is evaluating 
the efficacy and safety of adding aliskiren to optimized 
standard therapy in the prevention of LV remodeling in post 
acute myocardial infarction patients.61 The Aliskiren Trial 
in Type 2 Diabetes using Cardiovascular and Renal Disease 
Endpoints (ALTITUDE) is a placebo controlled trial designed 
to determine whether adding aliskiren to conventional therapy 
reduces cardiovascular and renal morbidity and mortality 
in high risk patients with type 2 diabetes.62 ALTITUDE is 
an event driven trial that aims to randomize 8600 patients 
with type 2 diabetes who are at high risk because of 
proteinuria, microalbuminuria accompanied by a reduced 
estimated glomerular filtration rate (eGFR), or a history of 
cardiovascular disease accompanied by a reduced eGFR with 
or without microalbuminuria to aliskiren 300 mg daily or 
placebo added to usual treatment. Multiple cardiovascular 
and renal endpoints, including death are planned, and the 
expected follow-up time will be 48 months.
Conclusion
Introduction of the DRI aliskiren has opened doors for newer 
possibilities in the therapy of hypertension and related target 
organ damage. Aliskiren has antihypertensive efficacy com-
parable to other classes of antihypertensive medications with 
a tolerability and safety profile similar to placebo. It also 
has additive antihypertensive effects when combined with 
these other drug classes. Preliminary studies of the effects 
of aliskiren on target organ damage demonstrate comparable 
or greater efficacy compared to other RAAS antagonists. 
Results of clinical outcome trials are needed to establish the 
role of this novel class of antihypertensive medication in the 
therapeutic armamentarium.
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